Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP-A16 for RSV prevention in infants
NCT07363837Phase 2Not yet recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SIBP-A16 in respiratory syncytial virus infection (RSV), sponsored by Shanghai Institute of Biological Products. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SIBP-A16
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07363837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363837.